European CRO Venn Life Sciences has agreed to pitch in on a major international study of a new stent that harmlessly dissolves in the body. In a deal worth €2.4 million ($3.1 million), Venn will assist in a multicountry effort to determine the safety and efficacy of a percutaneous coronary intervention device that melts away after doing its job. More